Previous 10 | Next 10 |
The Company earns $8 Million Phase 3 Milestone Payment WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventi...
3 Hot Penny Stocks For Your Early July Watchlist On July 6th, we are seeing a sizable amount of flat trading for penny stocks and blue chips. This comes as the Fed reported its latest minutes, stating that it could be ‘more restrictive’ if inflation does not fall. As we...
Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? PR Newswire NEW YORK , July 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ...
Verrica Pharmaceuticals ( NASDAQ: VRCA ) shows stock buying by insiders on July 5: 10% owner, Perceptive Advisors bought ~1.43M shares at $2.10 worth $3M; this bring his total share holding to 5.04M shares. President and CEO, Ted White bought 23,809 shares at $2.1 ...
Renalytix ( RNLX ) -28% on Q3 earnings release . Angion Biomedica ( ANGN ) -27% after it discontinued phase 2 trial of ANG-3070 in patients with kidney disease . Exicure ( XCUR ) -23% as it implements reverse-stock-split to get back Nasdaq com...
Verrica Pharmaceuticals ( NASDAQ: VRCA ) is down 6.5% after-hours after the firm has priced its underwritten public offering of 12M shares of its common stock at a price to the public of $2.10/share for expected gross proceeds of ~$25.2M. Underwriter are granted 30-day...
Verrica Pharmaceuticals ( NASDAQ: VRCA ) shares dropped ~8% in extended trading hours after the dermatology therapeutics company proposed public offering of common stock. Terms of the offering are yet to be determined. Underwriter may be granted a 30-day option to ...
Verrica Pharma (NASDAQ:VRCA) said on Tuesday that it held a Type A meeting with the U.S. Food and Drug Administration on June 27, for the resubmission and potential approval of the New Drug Application for VP-102 to treat molluscum contagiosum, a viral skin disease. "We are encouraged by...
WEST CHESTER, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company held a Type A meeting with the U.S. Food ...
New York, New York--(Newsfile Corp. - June 21, 2022) - Levi & Korsinsky, LLP notifies investors in Verrica Pharmaceuticals, Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) of a class action securities lawsuit. The lawsuit on behalf of Verrica investors has been commenced in the the Uni...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...